Wednesday, June 13, 2012

FDA Did Not Approve Regenicin (OTCBB: RGIN) Skin Graft

FDA Did Not Approve Regenicin (OTCBB: RGIN) Skin GraftOrlando, FL 6/13/12 (StreetBeat) – Regenicin (OTCBB:RGIN) has NOT received U.S. approval to sell a personalized skin graft for burn victims.

Investors were apparently fooled into believing otherwise Tuesday after the nearly bankrupt, penny-stock company issued a press release announcing "FDA Issues Orphan Status Approval for PermaDerm."

Shares of Regenicin rose 12 cents, or 80%, to 27 cents per share Tuesday on massive volume of 4.1 million shares. On a typical day, only 168,000 shares of Regenicin trade hands.

Yet if investors trading Regenicin Tuesday believed the company was on the cusp of selling PermaDerm, they're mistaken. The FDA action only granted Regenicin the right to pursue the clinical development of PermaDerm as a treatment for an orphan disease, or rare medical condition.

PermaDerm is still experimental and Regenicin, even with some of the shortcuts granted with an orphan disease product, still has to conduct clinical trials and seek FDA approval -- steps the company hasn't accomplished yet.

PermaDerm is a skin graft prepared using a sample of a patient's own skin. This skin sample is grown into a larger replacement graft that can be used later by surgeons to treat severe burn victims.

Regenicin hopes to start clinical trials of PermaDerm this year and request FDA approval in 2013, according to the company's most recent annual report filed with the Securities and Exchange Commission.

Importantly, PermaDerm has been in development for more than 20 years, during which U.S. regulators have issued multiples warning letters due to unreliable clinical data and improper testing procedures, according to a 2011 report by BioPharmCatalyst.

Regenicin is close to insolvency. The company, which is headquartered in the home of its CEO, finished the first quarter with only $36,000 in cash on hand. Since then, Regenicin has survived on high-interest loans from certain unnamed individuals, according to SEC filings.

Please contact for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment